PDF(Pubmed)
Abstract：
Hypercortisolism in dogs is frequently associated with systemic hypertension (SH). However, there are no studies evaluating the changes in systolic blood pressure (SBP) in dogs with adrenal-dependent hypercortisolism (ADH) during trilostane treatment or after adrenalectomy and their response to antihypertensive treatments. For this reason, the objectives of this study were to evaluate the changes in SBP in dogs with ADH during the first year of trilostane treatment or after adrenalectomy, the relation with clinical control of hypercortisolism and certain laboratory parameters, and the response to antihypertensive drugs. Fourteen dogs newly diagnosed with ADH were prospectively included and evaluated at diagnosis (T0) and 1, 3, 6, and 12 months after (T1, T3, T6, and T12, respectively). Dogs were classified as hypertensive (HT; SBP ≥ 160 mmHg) and non-hypertensive. In HT dogs, benazepril was considered as the first-line drug, and, if necessary, amlodipine was prescribed. The prevalence of SH at T0 was 79%, and it was reduced to 25% at T12. Blood pressure (BP) was not associated with disease control or selected laboratory parameters at any endpoint. Only 22% of dogs with SH needed more than one drug to normalize their SBP. In all dogs surgically treated that were HT at T0, BP normalized at T3.
摘要：
狗的皮质醇增多症通常与全身性高血压（SH）有关。然而,没有研究评估肾上腺依赖性皮质醇增多症(ADH)犬在接受三氯甾烷治疗期间或肾上腺切除术后收缩压(SBP)的变化及其对抗高血压治疗的反应.出于这个原因,这项研究的目的是评估犬ADH患者在治疗第一年或肾上腺切除术后的SBP变化，与皮质醇增多症的临床控制和某些实验室参数的关系，以及对降压药的反应。在诊断（T0）和1、3、6和12个月后（分别为T1、T3、T6和T12），前瞻性地纳入并评估了14只新诊断为ADH的狗。狗分为高血压（HT；SBP≥160mmHg）和非高血压。在HT狗中，贝那普利被认为是一线药物，and,如有必要,服用氨氯地平。T0时SH的患病率为79%,在T12时降至25%。在任何终点，血压（BP）与疾病控制或选定的实验室参数无关。只有22％的SH犬需要一种以上的药物来使其SBP正常化。在所有经手术治疗的狗中,在T0为HT,在T3为BP标准化。
